Business Wire

CA-DENODO

18.5.2021 09:02:11 CEST | Business Wire | Press release

Share
Latest Cloud Survey From Denodo Reveals Advanced Workloads Moving to the Cloud While Hybrid and Multi-Cloud Management Skills Are in High Demand

Data virtualization leader Denodo’s fourth annual cloud usage survey finds organizations are accelerating their cloud journey to take advantage of its flexibility, control costs, speed time-to-market, and simplify data management. According to survey respondents, which included 150 global business and IT professionals from various industry sectors, hybrid-cloud deployment remains the dominant choice, as more than a third of these organizations (35 percent) use this model. Private cloud has shown some vibrant usage, accounting for almost a quarter of all workloads (24 percent), followed by public cloud, which remained almost flat at 16 percent. Multi-cloud remains a popular choice for almost one in ten organizations (9 percent) who opt to procure best of breed applications, data repositories, and infrastructure orchestration technologies among different cloud service providers to avoid a single vendor lock-in.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210518005232/en/

The complimentary findings are available for download here .

Even though the number of organizations with some level of cloud adoption remained steady year-over-year, the percentage of organizations that are moving advanced workloads to the cloud has increased by 25 percent (19.59 percent in 2021 vs. 15.48 percent in 2020). While security and skills are still major concerns for organizations, the statistics clearly indicates that businesses are becoming more confident about moving their important workloads to the cloud and embracing cloud more than ever. In terms of cloud providers, AWS and Azure still hold the lion’s share of the cloud market (65 percent combined), while others like Google Cloud Platform (GCP) are slowly catching up.

As a sizeable percentage of organizations are cautiously putting their first step into the cloud, Marketplaces are becoming very popular as almost half (45 percent) are leveraging them to take advantage of various incentives, including low upfront investments and risks. Utility/pay-as-you-go pricing is the most popular motivation at 35 percent followed by its self-service capability/ability to minimize IT dependency (25 percent), and simplified procurement (14 percent). Avoiding a long-term commitment was also a motivator at 6 percent.

Companies are using cloud for various use cases with the top two popular being analytics and infrastructure usage, and AI/ML. AI/ML and stream processing use cases are showcasing their importance on how businesses are using those technologies for their day-to-day operations, as year-over-year growth for each ranged between 50 and 100 percent. Close to 50 percent of participants leverage multiple solutions for data integration in the cloud, the most popular ones being data lakes, ETL pipeline, cloud data warehouse and object storage.

As organizations embrace cloud faster than ever, IT processes are becoming more automated and agile through the adoption of microservices and containers. Fifty percent of survey respondents indicated that they are using Docker for automation and portability. Kubernetes adoption is also increasing at a steady pace, because for many organizations, hundreds and at times thousands of microservices span both on-premises IT environments and multiple clouds.

“While we already know that cloud has become an inevitable force in IT infrastructure management, with cloud migration challenges abound, organizations often do not have a clear path to cloud adoption,” said Ravi Shankar, senior vice president and chief marketing officer of Denodo. “For the last four years, our audience has been sharing how they see the path to a successful infrastructure modernization unfolding. Just like majority of our audience, I personally believe that a well laid out logical data fabric, created with data virtualization, may be the key to helping organizations embrace a hybrid or multi-cloud strategy that is easy to deploy, manage, and maintain.”

Methodology:

The 2021 Denodo Global Cloud Study surveyed 150 organizations in March 2021. Users from various backgrounds, roles and regions participated. The full report is available for download here .

Please Tweet: New survey from #datavirtualization leader @denodo reveals advanced workloads moving to the #cloud as organizations embrace #hybrid and #multi-cloud architectures

About Denodo

Denodo is the leader in data virtualization providing agile, high performance data integration, data abstraction, and real-time data services across the broadest range of enterprise, cloud, big data, and unstructured data sources at half the cost of traditional approaches. Denodo’s customers across every major industry have gained significant business agility and ROI by enabling faster and easier access to unified business information for agile BI, big data analytics, Web, cloud integration, single-view applications, and enterprise data services. Denodo is well-funded, profitable, and privately held. For more information, visit http://www.denodo.com or call +1 877 556 2531 / +44 (0) 20 7869 8053.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye